The Pharma Letter What FDA and EMA now accept from real-world data - The Pharma Letter ✦ European Medicines Agency (EMA) EMA and FDA set common principles for AI in medicine development - European Medicines Agency (EMA) ✦ BioPharm International FDA and EMA Requirements Converge for Cell and Gene Therapy CMC, but GMP Gaps Persist - BioPharm International ✦ The Medicine Maker How China Is Rewriting the Rules Global Drug Development - The Medicine Maker ✦ Global Market Insights Inc. Pharmaceutical CDMO Market Size, Report 2026-2035 - Global Market Insights Inc. ✦ Health Policy Watch EU And US Regulators Reach Landmark Accord On AI Principles In Drug Development - Health Policy Watch ✦ PR Newswire UK Altruist Biologics' Suzhou Site Receives EMA GMP Certification, Enabling Product Commercialization for the European Market - PR Newswire UK ✦ Fierce Biotech The 2026 Cell Therapy Regulatory Landscape: Aligning CMC Strategy with FDA and EMA Expectations - Fierce Biotech ✦ GlobeNewswire [Latest] Global In Silico Clinical Trials Market Size/Share - GlobeNewswire ✦ Business Wire Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T) - Business Wire ✦ The Pharma Letter What FDA and EMA now accept from real-world data - The Pharma Letter ✦ European Medicines Agency (EMA) EMA and FDA set common principles for AI in medicine development - European Medicines Agency (EMA) ✦ BioPharm International FDA and EMA Requirements Converge for Cell and Gene Therapy CMC, but GMP Gaps Persist - BioPharm International ✦ The Medicine Maker How China Is Rewriting the Rules Global Drug Development - The Medicine Maker ✦ Global Market Insights Inc. Pharmaceutical CDMO Market Size, Report 2026-2035 - Global Market Insights Inc. ✦ Health Policy Watch EU And US Regulators Reach Landmark Accord On AI Principles In Drug Development - Health Policy Watch ✦ PR Newswire UK Altruist Biologics' Suzhou Site Receives EMA GMP Certification, Enabling Product Commercialization for the European Market - PR Newswire UK ✦ Fierce Biotech The 2026 Cell Therapy Regulatory Landscape: Aligning CMC Strategy with FDA and EMA Expectations - Fierce Biotech ✦ GlobeNewswire [Latest] Global In Silico Clinical Trials Market Size/Share - GlobeNewswire ✦ Business Wire Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T) - Business Wire ✦